Dr. Reddy’s Laboratories’ latest earnings show a modest rise in profit, but the real story extends far beyond the headline numbers.
So, what’s driving this pharmaceutical powerhouse forward?
Our latest video analysis breaks down the Q2 FY26 results, uncovering the company’s focus on global generics expansion, cost optimization, and steady progress in biosimilars and specialty segments.
Watch the full, insightful analysis by AlphaStreet below: